6.67
+0.01(+0.15%)
Currency In USD
| Previous Close | 6.66 |
| Open | 6.5 |
| Day High | 6.7 |
| Day Low | 6.47 |
| 52-Week High | 11.31 |
| 52-Week Low | 6 |
| Volume | 5.35M |
| Average Volume | 4.45M |
| Market Cap | 1.41B |
| PE | -133.4 |
| EPS | -0.05 |
| Moving Average 50 Days | 7.32 |
| Moving Average 200 Days | 8.23 |
| Change | 0.01 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $948.79 as of January 21, 2026 at a share price of $6.67. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $728.96 as of January 21, 2026 at a share price of $6.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)– –ORLADEYO net revenue expected to be between $625 million and $645 million in 2026– –BioCry
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P